More on Ritonavir-Boosted Atazanavir Alone for Maintenance Therapy

In a small single-arm study of ritonavir-boosted atazanavir, 93% of patients maintained virologic suppression at 24 weeks. However, HIV remained detectable in 15% of CSF samples and 13% of semen samples.

Interest remains high in induction-maintenance antiretroviral strategies, wherein patients who achieve virologic suppression, without developing resistance, are switched to a simpler and possibly less-toxic and less-expensive maintenance regimen. Many of the older studies of this strategy used dual-NRTI or unboosted-PI maintenance regimens and produced disappointing results. More recently, investigators have been evaluating the role of boosted PIs, including ritonavir-boosted atazanavir, which showed promising results as maintenance therapy in a small ACTG pilot study (ACC Sep 18 2006).

In the present study, researchers in Switzerland evaluated ritonavir-boosted atazanavir as maintenance therapy, with a particular focus on the drugs’ penetra…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

More on Ritonavir-Boosted Atazanavir Alone for Maintenance Therapy

Topics

Reviewing Author